Abiraterone and novel antiandrogens: Overcoming castration resistance in prostate cancer

Annual Review of Medicine

Volumn 64, Issue , 2013, Pages 1-13

  Ferraldeschi, R ^a   Pezaro, C ^b   Karavasilis, V ^c   De Bono, J ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

abiraterone acetate; CRPC; CYP17 inhibitors; enzalutamide (MDV3100); resistance

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; CABAZITAXEL; CABOZANTINIB; CHOLESTEROL; CORTICOTROPIN; CYTOCHROME P450 17; DEXAMETHASONE; DOCETAXEL; ENZALUTAMIDE; EPLERENONE; ESTRADIOL; GALETERONE; KETOCONAZOLE; LUTEINIZING HORMONE; ORTERONEL; PLACEBO; PREDNISONE; PROGESTERONE; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T; TESTOSTERONE; UNCLASSIFIED DRUG; VELIPARIB; VN 124 1;

ANTIANDROGEN THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; DIARRHEA; DRUG TREATMENT FAILURE; EDEMA; FATIGUE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; HYPERTENSION; HYPOKALEMIA; ORCHIECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SEIZURE; SIDE EFFECT; SIGNAL TRANSDUCTION;

ANDROGEN ANTAGONISTS; ANDROGENS; ANDROSTENOLS; CASTRATION; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84873025061     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-121211-091605     Document Type: Review

References (73)

1. Siegel R, Naishadham D, Jemal A. 2012. Cancer statistics, 2012. CA Cancer J. Clin. 62:10-29
2. Crawford ED, Eisenberger MA, McLeod DG, et al. 1989. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 321:419-24
3. Eisenberger MA, Blumenstein BA, Crawford ED, et al. 1998. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. 339:1036-42
4. Tannock IF, deWit R, Berry WR, et al. 2004. Docetaxel plus prednisone ormitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351:1502-12
5. Petrylak DP, Tangen CM, Hussain MH, et al. 2004. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351:1513-20
6. Attard G, Cooper CS, de Bono JS. 2009. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 16:458-62
7. de Bono JS, Logothetis CJ, Molina A, et al. 2011. Abiraterone and increased survival inmetastatic prostate cancer. N. Engl. J. Med. 364:1995-2005
8. Scher HI, Fizazi K, Saad F, et al. 2012. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367:1187-97
9. Huggins CHC. 1941. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1:293-97
10. Hellerstedt BA, Pienta KJ. 2002. The current state of hormonal therapy for prostate cancer. CA Cancer J. Clin. 52:154-79
11. Stanbrough M, Bubley GJ, Ross K, et al. 2006. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66:2815-25
12. Montgomery RB, Mostaghel EA, Vessella R, et al. 2008. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68:4447-54
13. Locke JA, Guns ES, Lubik AA, et al. 2008. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68:6407-15
14. Trachtenberg J. 1984. Ketoconazole therapy in advanced prostatic cancer. J. Urol. 132:61-63
15. Oh WK. 2002. Secondary hormonal therapies in the treatment of prostate cancer. Urology 60:87-92; discussion 93
16. Potter GA, Barrie SE, Jarman M, et al. 1995. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17, 20-lyase): potential agents for the treatment of prostatic cancer. J. Med. Chem. 38:2463-71
17. Barrie SE, Potter GA, Goddard PM, et al. 1994. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J. Steroid Biochem. Mol. Biol. 50:267-73
18. Attard G, Belldegrun AS, de Bono JS. 2005. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 96:1241-46
19. O'Donnell A, Judson I, Dowsett M, et al. 2004. Hormonal impact of the 17alpha-hydroxylase/C(17, 20)- lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br. J. Cancer 90:2317-25
20. Attard G, Reid AH, Yap TA, et al. 2008. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26:4563-71
21. Attard G, Reid AH, A'Hern R, et al. 2009. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27:3742-48
22. Grigoryev DN, Long BJ, Njar VC, et al. 2000. Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor. J. Steroid Biochem. Mol. Biol. 75:1-10
23. Ryan CJ, Shah S, Efstathiou E, et al. 2011. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin. Cancer Res. 17:4854-61
24. Ryan CJ, Smith MR, Fong L, et al. 2010. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J. Clin. Oncol. 28:1481-88
25. Danila DC, Morris MJ, de Bono JS, et al. 2010. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol. 28:1496-501
26. Reid AH, Attard G, Danila DC, et al. 2010. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 28:1489-95
27. Scher H, Heller G, Molina A, et al. 2011. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J. Clin. Oncol. 29: (suppl; abstr LBA4517)
28. Ryan CJ, Smith MR, De Bono JS, et al. 2012. Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castrationresistant prostate cancer (mCRPC). J Clin Oncol. 30 (suppl): abstr LBA4518
29. Darshan MS, Loftus MS, Thadani-Mulero M, et al. 2011. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 71:6019-29
30. Gan L, Chen S, Wang Y, et al. 2009. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res. 69:8386-94
31. Taplin M, Montgomery RB, Logothetis C, et al. 2012. Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): results of a randomized phase II study. J. Clin. Oncol. 30 (suppl): abstr 4521
32. Yamaoka M, Hara T, Hitaka T, et al. 2012. Orteronel (TAK-700), a novel non-steroidal 17, 20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J. Steroid Biochem. Mol. Biol. 129:115-28
33. Dreicer R, Agus DB, MacVicar D, et al. 2010. Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant, metastatic prostate cancer: a phase I/II, open-label study. Presented at Genitourinary Cancers Symp., San Francisco, CA, Mar. 5-7
34. Bruno RD, Gover TD, Burger AM, et al. 2008. 17alpha-Hydroxylase/17, 20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Mol. Cancer Ther. 7:2828-36
35. Schayowitz A, Sabnis G, Njar VC, et al. 2008. Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Mol. Cancer Ther. 7:121-32
36. Montgomery RB. 2012. ARMOR1: safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy naïve patients with castration-resistant prostate cancer (CRPC). Presented at Annu. Meet. Am. Assoc. Cancer Res., Chicago, IL, Mar. 31-Apr. 4
37. Eisner JR, AbbottDH, Bird IM, et al. 2012. VT-464: a novel, selective inhibitor of P450c17(CYP17)-17, 20 lyase for castration-refractory prostate cancer (CRPC). J. Clin. Oncol. 30 (suppl): abstr e15167)
38. Mukherji D, Pezaro CJ, De-Bono JS. 2012. MDV3100 for the treatment of prostate cancer. Expert Opin. Investig. Drugs 21:227-33
39. Small EJ, Carroll PR. 1994. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 43:408-10
40. Taplin ME, Bubley GJ, Shuster TD, et al. 1995. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332:1393-98
41. Culig Z, Hoffmann J, Erdel M, et al. 1999. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br. J.Cancer 81:242-51
42. Linja MJ, Savinainen KJ, SaramakiOR, et al. 2001. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61:3550-55
43. Tran C, Ouk S, Clegg NJ, et al. 2009. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787-90
44. Scher HI, Beer TM, Higano CS, et al. 2010. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375:1437-46
45. Clegg NJ, Wongvipat J, Joseph JD, et al. 2012. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 72:1494-503
46. Tomlins SA, Rhodes DR, Perner S, et al. 2005. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-48
47. Attard G, Clark J, Ambroisine L, et al. 2008. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br. J. Cancer 99:314-20
48. Barbieri CE, Demichelis F, Rubin MA. 2012. Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. Histopathology 60:187-98
49. Carver BS, Chapinski C, Wongvipat J, et al. 2011. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19:575-86
50. Cai C, Chen S, Ng P, et al. 2011. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 71:6503-13
51. Mostaghel EA, Marck BT, Plymate SR, et al. 2011. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin. Cancer Res. 17:5913-25
52. Efstathiou E, Titus M, Tsavachidou D, et al. 2012. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J. Clin. Oncol. 30:637-43
53. Luthy IA, Begin DJ, Labrie F. 1988. Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J. Steroid Biochem. 31:845-52
54. Richards J, Lim AC, Hay CW, et al. 2012. Interactions of abiraterone, eplerenone and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 72(9):2176-82
55. Attard G, Reid AH, Auchus RJ, et al. 2012. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castratemen with advanced prostate cancer. J. Clin. Endocrinol. Metab. 97:507-16
56. Zhang X, Morrissey C, Sun S, et al. 2011. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One 6:e27970
57. Watson PA, Chen YF, Balbas MD, et al. 2010. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc. Natl. Acad. Sci. USA 107:16759-65
58. Andersen RJ, Mawji NR, Wang J, et al. 2010. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17:535-46
59. Culig Z. 2004. Androgen receptor cross-talk with cell signalling pathways. Growth Factors 22:179-84
60. Efstathiou E, Titus MA, Tsavachidou D, et al. 2011. MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: a preliminary report. J. Clin. Oncol. 29(Suppl.):Abstr. 4501
61. Vanaja DK, Mitchell SH, Toft DO, et al. 2002. Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones 7:55-64
62. Pacey S, Wilson RH, Walton M, et al. 2011. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin. Cancer Res. 17:1561-70
63. Heath EI, Hillman DW, Vaishampayan U, et al. 2008. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Cancer Res. 14:7940-46
64. Neckers L, Workman P. 2012. Hsp90 molecular chaperone inhibitors: Are we there yet? Clin. Cancer Res. 18:64-76
65. Kim NC. 2012. A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. J. Clin. Oncol. 30(Suppl. 5):Abstr. 121
66. Attard G, Swennenhuis JF, Olmos D, et al. 2009. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 69:2912-18
67. Shaffer DR, Leversha MA, Danila DC, et al. 2007. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin. Cancer Res. 13:2023-29
68. Weckermann D, Polzer B, Ragg T, et al. 2009. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J. Clin. Oncol. 27:1549-56
69. Scher HI, Morris MJ, Basch E, et al. 2011. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J. Clin. Oncol. 29:3695-704
70. de Bono JS, Scher HI, Montgomery RB, et al. 2008. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14:6302-9
71. Olmos D, Arkenau HT, Ang JE, et al. 2009. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann. Oncol. 20:27-33
72. Scher HI, Jia X, de Bono JS, et al. 2009. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 10:233-39
73. Yap TA, Zivi A, Omlin A, et al. 2011. The changing therapeutic landscape of castration-resistant prostate cancer. Nat. Rev. Clin. Oncol. 8:597-610